Feed:All articles/Pretty: Difference between revisions

Jump to navigation Jump to search

Feed:All articles/Pretty (view source)

Revision as of 18:19, 3 September 2024

2,454 bytes removed ,  3 September 2024
no edit summary
No edit summary
No edit summary
Tag: Reverted
Line 7,488: Line 7,488:
             "title" : "Closure of patent foramen ovale versus medical therapy after cryptogenic stroke",
             "title" : "Closure of patent foramen ovale versus medical therapy after cryptogenic stroke",
             "pmid" : "23514286"
             "pmid" : "23514286"
        },
        {
            "timestamp" : "2017-12-03T22:39:03Z",
            "briefDesignDescription" : "Rifaximin/lactulose vs. lactulose for acute HE",
            "fulltexturl" : "http://www.nature.com/ajg/journal/v108/n9/full/ajg2013219a.html",
            "pageid" : 1784,
            "pdfurl" : "http://www.nature.com/ajg/journal/v108/n9/pdf/ajg2013219a.pdf",
            "trainingLevel" : "Intern",
            "citation" : "Sharma BC, <i>et al</i>. \"A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy\". <i>The American Journal of Gastroenterology</i>. 2013. 108(9):1458-1463.",
            "subspecialties" : "Gastroenterology",
            "expansion" : "",
            "statusUsableDate" : "2014-03-01",
            "briefResultsDescription" : "Rifaximin/lactulose improved rates of HE reversal and survival, reduced hospital LOS",
            "published" : "2013-09-01",
            "pageName" : "Rifaximin and Lactulose for HE",
            "diseases" : "Hepatic Encephalopathy",
            "abbreviation" : "",
            "title" : "A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy",
            "pmid" : "23877348"
        },
        {
            "timestamp" : "2022-03-10T21:09:46Z",
            "briefDesignDescription" : "Rituximab in ANCA-Renal Vasculitis",
            "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/nejmoa0909169",
            "pageid" : 4459,
            "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa0909169",
            "trainingLevel" : "fellow",
            "citation" : "Jones RB, <i>et al</i>. \"Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis\". <i>The New England Journal of Medicine</i>. 2010. 363(3):211-232.",
            "subspecialties" : "Rheumatology;Nephrology",
            "expansion" : "",
            "statusUsableDate" : "2022-03-10",
            "briefResultsDescription" : "Rituximab not superior to cyclophosphamide",
            "published" : "2010-07-15",
            "pageName" : "RITUXVAS",
            "diseases" : "Vasculitis;ANCA-Associated Vasculitis;Renal Vasculitis",
            "abbreviation" : "RITUXVAS",
            "title" : "Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis",
            "pmid" : "20647198"
         },
         },
         {
         {
WJCBot
Bots, editor, reviewer, Administrators
13,941

edits

Retrieved from "http://www.wikijournalclub.org/wiki/Special:MobileDiff/43238"

Navigation menu